Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects
Open Access
- 12 March 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 113 (11), 2547-2556
- https://doi.org/10.1182/blood-2009-05-155689
Abstract
High levels of granulocyte/macrophage–colony-stimulating factor (GM-CSF) autoantibodies are thought to cause pulmonary alveolar proteinosis (PAP), a rare syndrome characterized by myeloid dysfunction resulting in pulmonary surfactant accumulation and respiratory failure. Paradoxically, GM-CSF autoantibodies have been reported to occur rarely in healthy people and routinely in pharmaceutical intravenous immunoglobulin (IVIG) purified from serum pooled from healthy subjects. These findings suggest that either GM-CSF autoantibodies are normally present in healthy people at low levels that are difficult to detect or that serum pooled for IVIG purification may include asymptomatic persons with high levels of GM-CSF autoantibodies. Using several experimental approaches, GM-CSF autoantibodies were detected in all healthy subjects evaluated (n = 72) at low levels sufficient to rheostatically regulate multiple myeloid functions. Serum GM-CSF was more abundant than previously reported, but more than 99% was bound and neutralized by GM-CSF autoantibody. The critical threshold of GM-CSF autoantibodies associated with the development of PAP was determined. Results demonstrate that free serum GM-CSF is tightly maintained at low levels, identify a novel potential mechanism of innate immune regulation, help define the therapeutic window for potential clinical use of GM-CSF autoantibodies to treat inflammatory and autoimmune diseases, and have implications for the pathogenesis of PAP.Keywords
This publication has 48 references indexed in Scilit:
- Characteristics of a Large Cohort of Patients with Autoimmune Pulmonary Alveolar Proteinosis in JapanAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Anti‐cytokine autoantibodies are ubiquitous in healthy individualsFEBS Letters, 2007
- A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSFMolecular Immunology, 2007
- Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to controlMycobacterium tuberculosisinfectionJournal of Leukocyte Biology, 2005
- Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4American Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosisThorax, 2003
- GM-CSF, via PU.1, regulates alveolar macrophage FcγR-mediated phagocytosis and the IL-18/IFN-γ–mediated molecular connection between innate and adaptive immunity in the lungBlood, 2002
- Granulocyte Macrophage Colony-Stimulating FactorThe Journal of Experimental Medicine, 2001
- Probability-based protein identification by searching sequence databases using mass spectrometry dataElectrophoresis, 1999
- Involvement of Granulocyte-Macrophage Colony-Stimulating Factor in Pulmonary HomeostasisScience, 1994